

COVID-19 Vaccine Clinical Info and Resources

CDC Clinical Info on COVID-19 Vaccine and its Side Effects

As we begin COVID-19 vaccination administration to our staff and residents, it is important to understand the side effects of the inoculation.

The CDC released guidance to help health care providers differentiate between a possible COVID infection and vaccine reactions. [This slide show](#) gives an overview of this information and contains links within it to CDC guidance. It also discusses how vaccine side effects will be monitored by the recipient through the V-Safe monitoring system and the VAERS system.

- To access information about Post Vaccine Considerations for Health Care Personnel go here: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/post-vaccine-considerations-healthcare-personnel.html>.

Resources from the AMDA The Society for Post-Acute and Long-Term Care Medicine

The American Medical Directors Association/ The Society for Post-Acute and Long-Term Care Medicine has several helpful resources.

- [PowerPoint presentation “COVID-19 Vaccine Hesitancy and Education” A Guide for Medical Directors](#)
- [Q and A about the COVID-19 vaccine for staff, patients, residents and family members](#)

Guidance from AHCA Related to Workforce and Vaccine

<https://www.ahcancal.org/Survey-Regulatory-Legal/Emergency-Preparedness/Documents/COVID19/Staffing-Post-Vaccine.pdf>

Mayo Clinic article debunks COVID-19 vaccine myths

The Mayo Clinic recently published an article debunking COVID-19 vaccine myths. You can read the article [here](#).

Post Vaccine Considerations for Healthcare Personnel

Strategies are needed for healthcare facilities to appropriately evaluate and manage post-vaccination signs and symptoms among healthcare personnel. [These considerations](#) are based on the current understanding of signs and symptoms following COVID-19 vaccination, including timing and duration, and might change as experience with the vaccine accumulates.

Interim Clinical Considerations for Use of Pfizer-BioNTech COVID-19 Vaccine

On December 12, 2020, the Advisory Committee on Immunization Practices issued an [interim recommendation](#) for use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 in persons aged 16 years and older. The Pfizer-BioNTech COVID-19 vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. To learn more, please visit: [Vaccines & Immunizations](#).

Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine

Among all study vaccine recipients asked to complete diaries of their symptoms during the 7 days after vaccination, 84.7% reported at least one local injection site reaction. By age group, 88.7% in the younger group (aged 18 to 55 years) and 79.7% in the older group (aged >55 years) reported at least one local reaction. To learn more, please visit: [Local Reactions](#).

Pfizer-BioNTech COVID-19 Vaccine

The new [Pfizer-BioNTech COVID-19 Vaccine webpage](#) has information specific to Pfizer's vaccine, including resources to assist providers in storing, handling, and administering the vaccine.